Menstrual and Other Female Reproductive System Disorders DRG Reimbursement

DRG 760 encompasses inpatient admissions for menstrual and other female reproductive system disorders with at least one Complication or Comorbidity or Major Complication or Comorbidity, covering conditions such as significant gynecologic hemorrhage, severe dysmenorrhea with complications, and other reproductive tract disorders requiring hospital care. This Diagnosis-Related Group is important for inpatient reimbursement because the Complication or Comorbidity and Major Complication or Comorbidity status influences Medicare payment levels and reflects increased resource use.

DRG 760 Overview

DRG 760 covers hospital admissions for menstrual and other female reproductive system disorders when accompanied by at least one Complication or Comorbidity or Major Complication or Comorbidity. Typical cases include significant gynecologic bleeding, severe pelvic pain with associated comorbid conditions, and other disorders requiring inpatient management and possible surgical or medical interventions. This Diagnosis-Related Group matters for Medicare payment because the presence of Complication or Comorbidity or Major Complication or Comorbidity elevates payment relative to non-Complication or Comorbidity cases and affects resource intensity and payment tiering under Medicare rules. Accurate coding of principal and secondary diagnoses is therefore essential to align reimbursement with clinical complexity.

Acute procedural and perioperative management studies: randomized or observational trials evaluating techniques, timing, and perioperative care for surgical interventions common in this DRG population (for example, endometrial ablation, hysteroscopy with polypectomy, or urgent gynecologic procedures for hemorrhage). These studies enroll hospitalized reproductive‑age and perimenopausal patients presenting with acute bleeding, severe pain, or complications of benign reproductive disorders to compare blood loss control, transfusion rates, perioperative complications, and length of stay. Evidence from this type of research informs inpatient clinical pathways, resource utilization, and coding/DRG optimization for providers and payers by identifying approaches that reduce complications and shorter hospitalization.
Comparative effectiveness trials of medical versus procedural management: pragmatic trials or large observational cohorts comparing pharmacologic therapies (for example, hormonal regimens or antifibrinolytics) against minimally invasive procedures for symptomatic menorrhagia or other benign reproductive disorders with comorbid conditions (CC/MCC). These studies focus on patients with significant comorbidity (anemia, bleeding disorders, anticoagulation) or contraindications to surgery to determine symptom control, need for subsequent inpatient admission, readmission rates, and health‑related quality of life. Results are relevant to payers and hospitals in guiding care pathways, reimbursement decisions, and preauthorization policies by clarifying which patients benefit from inpatient versus outpatient management.
Post‑discharge outcomes, utilization, and readmission prevention research: cohort studies and quality‑improvement trials examining post‑hospital outcomes such as 30‑ and 90‑day readmissions, transfusion dependence, outpatient follow‑up adherence, and functional recovery among patients discharged after inpatient treatment for menstrual and other reproductive system disorders with CC/MCC. These investigations include diverse populations with social determinants that affect recovery (older reproductive‑age women, those with chronic medical comorbidities, or limited outpatient access) to identify predictors of costly readmissions and opportunities for transitional care interventions. Findings help providers and payers design discharge planning, case management, and bundled payment strategies to reduce avoidable resource use and improve value for this DRG.

Acute procedural and perioperative management studies: randomized or observational trials evaluating techniques, timing, and perioperative care for surgical interventions common in this DRG population (for example, endometrial ablation, hysteroscopy with polypectomy, or urgent gynecologic procedures for hemorrhage). These studies enroll hospitalized reproductive‑age and perimenopausal patients presenting with acute bleeding, severe pain, or complications of benign reproductive disorders to compare blood loss control, transfusion rates, perioperative complications, and length of stay. Evidence from this type of research informs inpatient clinical pathways, resource utilization, and coding/DRG optimization for providers and payers by identifying approaches that reduce complications and shorter hospitalization.
Comparative effectiveness trials of medical versus procedural management: pragmatic trials or large observational cohorts comparing pharmacologic therapies (for example, hormonal regimens or antifibrinolytics) against minimally invasive procedures for symptomatic menorrhagia or other benign reproductive disorders with comorbid conditions (CC/MCC). These studies focus on patients with significant comorbidity (anemia, bleeding disorders, anticoagulation) or contraindications to surgery to determine symptom control, need for subsequent inpatient admission, readmission rates, and health‑related quality of life. Results are relevant to payers and hospitals in guiding care pathways, reimbursement decisions, and preauthorization policies by clarifying which patients benefit from inpatient versus outpatient management.
Post‑discharge outcomes, utilization, and readmission prevention research: cohort studies and quality‑improvement trials examining post‑hospital outcomes such as 30‑ and 90‑day readmissions, transfusion dependence, outpatient follow‑up adherence, and functional recovery among patients discharged after inpatient treatment for menstrual and other reproductive system disorders with CC/MCC. These investigations include diverse populations with social determinants that affect recovery (older reproductive‑age women, those with chronic medical comorbidities, or limited outpatient access) to identify predictors of costly readmissions and opportunities for transitional care interventions. Findings help providers and payers design discharge planning, case management, and bundled payment strategies to reduce avoidable resource use and improve value for this DRG.

OpenPayer

Summary & Overview

Menstrual and Other Female Reproductive System Disorders with CC/MCC: Inpatient Reimbursement Overview

DRG 760 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes